Michael E. Kamarck - 17 Nov 2021 Form 4 Insider Report for Trillium Therapeutics Inc.

Role: Director
Signature: /s/ James Parsons, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 17 Nov 2021
Net transactions value: $0
Form type: 4
Filing time: 19 Nov 2021, 12:28:05 UTC
Previous filing: 29 Oct 2021
Next filing: 03 Jun 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRIL	Stock Option (Right to Buy)	Disposed to Issuer	$0	-67,000	-100%	$0.000000^*	0	17 Nov 2021	Common Shares	67,000	$14.77	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Michael E. Kamarck is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.

Content

On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.